Kết quả tìm kiếm - Jeffrey Matous

Tinh chỉnh kết quả
  1. 1
    A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

    A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Bằng James R. Berenson, Jeffrey Matous, Regina A. Swift, Russell Mapes, Blake Morrison, Howard Yeh

    Được phát hành 2007
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  2. 2
    Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia

    Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia Bằng Ian W. Flinn, Mohamad Cherry, Michael B. Maris, Jeffrey Matous, Jesús G. Berdeja, Manish R. Patel

    Được phát hành 2019
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  3. 3
    Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment

    Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment Bằng Baiteng Zhao, Robert Chen, Owen A. O’Connor, Ajay K. Gopal, Radhakrishnan Ramchandren, André Goy, Jeffrey Matous, Adedigbo A. Fasanmade, Thomas Manley, Tae Hyung Han

    Được phát hành 2016
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  4. 4
    CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies

    CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies Bằng Tae Hyung Han, Ajay K. Gopal, Radhakrishnan Ramchandren, André Goy, Robert Chen, Jeffrey Matous, Maureen Cooper, Laurie E. Grove, Stephen C. Alley, Carmel M. Lynch, Owen A. O’Connor

    Được phát hành 2013
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  5. 5
    Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma

    Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma Bằng Sham Mailankody, Jeffrey Matous, Michaela Liedtke, Surbhi Sidana, Shahbaz A. Malik, Rajneesh Nath, Olalekan O. Oluwole, Erin E. Karski, Wade Lovelace, Xiangdong Zhou, Srinand Ponnathapura Nandakumar, Arun Balakumaran, Parameswaran Hari

    Được phát hành 2020
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  6. 6
    Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

    Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation Bằng Ajay K. Gopal, Radhakrishnan Ramchandren, Owen A. O’Connor, R.B. Berryman, Ranjana H. Advani, Robert Chen, Scott E. Smith, Maureen Cooper, Achim Rothe, Jeffrey Matous, Laurie E. Grove, Jasmine Zain

    Được phát hành 2012
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  7. 7
    Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide

    Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide Bằng Paul Shaughnessy, Miguel Islas‐Ohlmayer, Julie A. Murphy, Maureen Hougham, Jill MacPherson, Kurt Winkler, Matthew J. Silva, Michael Steinberg, Jeffrey Matous, Sheryl Selvey, Michael B. Maris, Peter A. McSweeney

    Được phát hành 2010
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  8. 8
    Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

    Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia Bằng Steven P. Treon, Andrew R. Branagan, Leukothea Ioakimidis, Jacob D. Soumerai, Christopher J. Patterson, Barry Turnbull, Parveen Wasi, Christos Emmanouilides, Stanley R. Frankel, Andrew Lister, Pierre Morel, Jeffrey Matous, Stephanie A. Gregory, Eva Kimby

    Được phát hành 2008
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  9. 9
    S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY

    S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY Bằng Fritz Offner, O. Decaux, Cyrille Hulin, Sébastien Anguille, Anne Sophie Michallet, Luciano J. Costa, Cyrille Touzeau, Kevin Boyd, Deeksha Vishwamitra, Yue Guo, Zhuolu Niu, Julie S. Larsen, Lingling Chen, Arnob Banerjee, Jenna D. Goldberg, Jeffrey Matous

    Được phát hành 2023
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  10. 10
    Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

    Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study Bằng Barbara Pro, Ranjana H. Advani, Pauline Brice, Nancy L. Bartlett, Joseph D. Rosenblatt, Tim Illidge, Jeffrey Matous, Radhakrishnan Ramchandren, Michelle A. Fanale, Joseph M. Connors, Yin Yang, Eric L. Sievers, Dana A. Kennedy, Andrei R. Shustov

    Được phát hành 2012
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  11. 11
    Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

    Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies Bằng Nancy L. Bartlett, Robert Chen, Michelle A. Fanale, Pauline Brice, Ajay K. Gopal, Scott E. Smith, Ranjana H. Advani, Jeffrey Matous, Radhakrishnan Ramchandren, Joseph D. Rosenblatt, Dirk Huebner, Pamela Levine, Laurie E. Grove, Andres Forero‐Torres

    Được phát hành 2014
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  12. 12
    Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study

    Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study Bằng Jeffrey Matous, Noa Biran, Aurore Perrot, Jesús G. Berdeja, Kathleen A. Dorritie, Janine van Elssen, Emma Searle, Cyrille Touzeau, Sébastien Anguille, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Katherine A. Thornton, Damiette Smit, Hang Quach

    Được phát hành 2023
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  13. 13
    Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia

    Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia Bằng Irene M. Ghobrial, Fangxin Hong, Swaminathan P. Iyer, Ashraf Badros, Meghan Rourke, Renee Leduc, Stacey Chuma, Janet Kunsman, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon, Edie Weller, Jeffrey Matous

    Được phát hành 2010
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  14. 14
    Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study

    Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study Bằng Nathan Fowler, Brad S. Kahl, Peter P. Lee, Jeffrey Matous, Amanda F. Cashen, Samuel A. Jacobs, Jeffrey Letzer, Bipinkumar Amin, Michael E. Williams, Sonali M. Smith, Alfred Saleh, Peter J. Rosen, Hongliang Shi, Sudha Parasuraman, Bruce D. Cheson

    Được phát hành 2011
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  15. 15
    Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

    Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma Bằng Barbara Pro, Ranjana H. Advani, Pauline Brice, Nancy L. Bartlett, Joseph D. Rosenblatt, Tim Illidge, Jeffrey Matous, Radhakrishnan Ramchandren, Michelle A. Fanale, Joseph M. Connors, Keenan Fenton, Dirk Huebner, Juan Pinelli, Dana A. Kennedy, Andrei R. Shustov

    Được phát hành 2017
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  16. 16
    Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

    Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia Bằng Irene M. Ghobrial, Federico Campigotto, Timothy J. Murphy, Erica N Boswell, Ranjit Banwait, Feda Azab, Stacey Chuma, Janet Kunsman, Amanda Donovan, Farzana Masood, Diane Warren, Scott J. Rodig, Kenneth C. Anderson, Paul G. Richardson, Edie Weller, Jeffrey Matous

    Được phát hành 2013
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  17. 17
    Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone—Results of a Multicenter Phase III Study

    Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol A... Bằng Jorge E. Cortés, Joseph O. Moore, Richard T. Maziarz, Meir Wetzler, Michael Craig, Jeffrey Matous, Selina M. Luger, Bimalangshu R. Dey, Gary J. Schiller, Dat C. Pham, Camille N. Abboud, Muthuswamy Krishnamurthy, Archie W. Brown, Abderrahmane Laadem, Karen Seiter

    Được phát hành 2010
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  18. 18
    Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

    Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia Bằng Irene M. Ghobrial, Wanling Xie, Swaminathan P. Iyer, Ashraf Badros, Meghan Rourke, Renee Leduc, Stacey Chuma, Janet Kunsman, Diane Warren, Tiffany Poon, Brianna Harris, Amy Sam, Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon, Edie Weller, Jeffrey Matous

    Được phát hành 2010
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  19. 19
    Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

    Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma Bằng Christine Chen, Donna Reece, David S. Siegel, Rubén Niesvizky, Ralph V. Boccia, Edward A. Stadtmauer, Rafat Abonour, Paul G. Richardson, Jeffrey Matous, Shaji Kumar, Nizar J. Bahlis, Melissa Alsina, Robert Vescio, Steven Coutré, Dennis Pietronigro, Robert Knight, Jerome B. Zeldis, S. Vincent Rajkumar

    Được phát hành 2009
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  20. 20
    Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180

    Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180 Bằng Steven P. Treon, Leukothea Ioakimidis, Jacob D. Soumerai, Christopher J. Patterson, Patricia Sheehy, Marybeth Nelson, Michael A. Willen, Jeffrey Matous, John Q. A. Mattern, Jakow G. Diener, George P. Keogh, Thomas J. Myers, Andy Boral, Ann Birner, Dixie Esseltine, Irene M. Ghobrial

    Được phát hành 2009
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:

Công cụ tìm kiếm: